Results with RAPTIVA

RAPTIVA is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. To view Clinical Data or Case Studies for a specific patient group, select from a treatment focus area below.

• 
• RAPTIVA for Plaque Psoriasis
  • Clinical Data
  • Case Studies
  
  
• RAPTIVA is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

• 
• RAPTIVA for Patients 200 lbs. & Above
  • Clinical Data
  • Case Studies
  
  
• RAPTIVA is the only therapy that has demonstrated consistent efficacy and long-term maintenance of response in patients 200 lbs. and above.

• 
• RAPTIVA for Hand & Foot Psoriasis
  • Clinical Data
  • Case Studies
  
  
• RAPTIVA demonstrated safety and efficacy in the only randomized, placebo-controlled clinical trial of a biologic for chronic plaque psoriasis involving the hands and feet.